

### TGA use only

Committee session:

Date approved:

Regulatory area:

Reference:

This form, when completed, will be classified as 'For official use only'. For guidance on how your information will be treated by the TGA see: Treatment of information provided to the TGA at <a href="http://www.tga.gov.au/about/tga-information-to.htm">http://www.tga.gov.au/about/tga-information-to.htm</a>.

# Proposed name for a chemical substance (AAN) used in therapeutic goods

## Application form

**Please note:** This application will be considered by the TGA's Australian Approved Names (AAN) Committee. The Committee will endeavour to consider the application within 20 working days. Following consideration, the Committee may ask the application for additional information where the application is incomplete or unclear, e.g. where the substance has not been clearly defined.

Refer to <u>TGA approved terminology of medicines</u> Section 1 – Chemical Substances – 1.1 Explanatory Notes for information on the naming of chemical substances.

Please note that the Committee only reviews the name and definition of an ingredient. The use of an ingredient is approved by other areas of the TGA.

1. Proposed chemical substance name				
2. Synonym(s)				
3. Structure and/or definition: (Including waters of hydration)				





4. The substance is expected to be used as:								
Active ingredient:   Excipier	nt ingredient:							
5. The substance is expected to be used in a:								
Listed medicine								
Prescription Medicine								
Orphan drug?	Yes 🗌	No 🗌						
Over the counter (OTC) medicine								
Registered complementary medicine								
Proprietary Ingredient Formulation								
Device								
Export only medicine								
6. Product name (if known):								
7. Route of administration:								
Oral 🗌	Topical 🗌		Other (please specify)					
Please specify:								

#### 8. References

This section must be completed. Please place a tick in the box next to the reference(s) containing the proposed name, and enter the reference details (edition, volume, etc.).

The reference(s) must refer to the name proposed, and a full copy of the relevant reference(s) must be provided.

TGA naming policy is to use the International Non-proprietary Name (INN) for a substance, wherever one exists. If an INN exists for a given substance, the applicant must justify the use of an alternative name. References are listed in approximate order of preference.

**Note on citations:** When citing a print version, provide full details including title, author details if applicable, edition, volume and pagination.

When citing an electronic version, provide full details including title, authority and platform where applicable, including version number. Specify medium accessed (for example web, CD-ROM). For internet sites, also provide the URL and date accessed.

	Ref. Code	Edition, Year, Volume	Reference
	INN		International Non-proprietary Names
	BP		British Pharmacopoeia
	BAN		British Approved Names
	USP		United States Pharmacopoeia
	USAN		United States Adopted Name
	ВРАР		British Pharmacopoeia - Appendix
	EP		European Pharmacopoeia
	MAR		Martindale, the Extra Pharmacopoeia
	MI		Merck Index
	FCC		Food Chemicals Codex
	ANZFS		Australia New Zealand Food Standards Code
	ICID		International Cosmetic Ingredient Dictionary
	CAS		CAS Registry (Chemical Abstracts Service)
	СНЕМ		CHEMID plus (National Library of Medicine)
	CI		Colour Index (Society of Dyers and Colourists)
	ALL		Allured's Flavour and Fragrance Materials
	FHF		Fenaroli's Handbook of Flavour Ingredients
	FIE		Fiedler Encyclopedia of Excipients
	HPE		Handbook of Pharmaceutical Excipients
Othe	er (please specif	y):	

## 9. Applicant details

Name		Sponsor:	Agent:
Position			
Company			
Client ID			
Address			
Telephone	Fax		
Email			

The completed form and attachments can be sent by email or post:

Email: TGAnames@tga.gov.au

Post: The Secretariat

Australian Approved Names Committee

Office of Scientific Evaluation
Therapeutic Goods Administration

PO BOX 100

WODEN ACT 2602